1. Emerging roles and mechanisms of FOXC2 in cancer
    Teng Wang et al, 2018, Clinica Chimica Acta CrossRef
  2. Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy
    Ji Yang et al, 2017, Tumor Biology CrossRef
  3. Members of FOX family could be drug targets of cancers
    Jinhua Wang et al, 2018, Pharmacology & Therapeutics CrossRef
  4. Genistein induces apoptosis of colon cancer cells by reversal of epithelial-to-mesenchymal via a Notch1/NF-κB/slug/E-cadherin pathway
    Panpan Zhou et al, 2017, BMC Cancer CrossRef
  5. Competitive endogenous RNA in colorectal cancer: A systematic review
    Han Shuwen et al, 2018, Gene CrossRef
  6. New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets
    Pooneh Mokarram et al, 2017, Autophagy CrossRef
  7. Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones
    Tânia R. Mielcke et al, 2017, Scientific Reports CrossRef

  8. FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer


    Yihong Chen et al, 2020, OncoTargets and Therapy CrossRef
  9. RNA-seq Analysis of Wild-Type vs. FOXC2-Deficient Melanoma Cells Reveals a Role for the FOXC2 Transcription Factor in the Regulation of Multiple Oncogenic Pathways
    Kristian M. Hargadon et al, 2020, Frontiers in Oncology CrossRef
  10. Long non-coding RNA GClnc1 knockdown suppresses progression of epithelial ovarian cancer by recruiting FOXC2 to disrupt the NOTCH1/NF-κB/Snail pathway
    Dandan Wu et al, 2021, Experimental Cell Research CrossRef
  11. High expression of forkhead box protein C2 is associated with aggressive phenotypes and poor prognosis in clinical hepatocellular carcinoma
    Yuki Shimoda et al, 2018, BMC Cancer CrossRef
  12. The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer
    Mehran Pashirzad et al, 2021, Current Cancer Drug Targets CrossRef
  13. Licochalcone A improves the cognitive ability of mice by regulating T- and B-cell proliferation
    Yating Wu et al, 2021, Aging CrossRef
  14. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs
    Peng Xing et al, 2023, Drug Resistance Updates CrossRef
  15. The FENDRR/FOXC2 Axis Contributes to Multidrug Resistance in Gastric Cancer and Correlates With Poor Prognosis
    Hao Liu et al, 2021, Frontiers in Oncology CrossRef
  16. Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective
    Kristian M. Hargadon et al, 2022, Cancer and Metastasis Reviews CrossRef
  17. The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer
    Kristian M. Hargadon et al, 2023, Technology in Cancer Research & Treatment CrossRef
  18. The prognostic significance of FOXC2 gene expression in cancer: A comprehensive analysis of RNA-seq data from the cancer genome atlas
    Kristian M. Hargadon et al, 2021, Cancer Genetics CrossRef
  19. Micro ribonucleic acid‐363 regulates the phosphatidylinositol 3‐kinase/threonine protein kinase axis by targeting NOTCH1 and forkhead box C2, leading to hepatic glucose and lipids metabolism disorder in type 2 diabetes mellitus
    Yu‐Huan Peng et al, 2022, Journal of Diabetes Investigation CrossRef
  20. FOXC2 Disease Mutations Identified in Lymphedema Distichiasis Patients Impair Transcriptional Activity and Cell Proliferation
    Daniela Tavian et al, 2020, International Journal of Molecular Sciences CrossRef